Transfusion 2024 Review Progress
Infected Blood Inquiry · Infected Blood Inquiry Final Report · Issued 20 May 2024 · Addressed to: UK Government
Source — verbatim from the inquiry
●Inquiry recommendation
Review of progress towards the Transfusion 2024 recommendations:
Progress in implementation of the Transfusion 2024 recommendations be reviewed, and next steps be determined and promulgated; and that in Scotland the 5 year plan is reviewed in or before 2027 with a view to determining next steps.
Infected Blood Inquiry, Infected Blood Inquiry Final Report · 20 May 2024 Source PDF →
Published evidence summary
Publicly available evidence relating to this recommendation:
- The Government stated in December 2024 that progress against Transfusion 2024 recommendations had been initially reviewed jointly by NHS England and NHSBT, and that a wider four-nation stakeholder review was being scheduled (Government Response to the Infected Blood Inquiry, Cabinet Office, December 2024).
- Scotland stated that the five-year plan would be reviewed in or before 2027 (Government Response to the Infected Blood Inquiry, Cabinet Office, December 2024).
- No published outcome from the Transfusion 2024 review has been identified to March 2026.
Response — verbatim from government
●UK Government
UK Government
Progress against Transfusion 2024 recommendations has been initially reviewed jointly by NHS England and NHSBT and a wider four nations stakeholder review is being scheduled. The draft report was discussed with key stakeholders at the end of November 2024 with further input underway in April/May 2025, and finalisation of the full report during the first quarter of 2025/26. Key aspects have been incorporated into the Transfusion Transformation Strategy (TTS).
The TTS is focusing on the next 5-10 years, amalgamating progress, learnings and future ambition in this area. Sub-recommendations from the working group on recommendation 7 are expected to be incorporated into the TTS, to provide a coherent future forward implementation plan for blood transfusion practices. This includes the potential creation of a National Blood Transfusion Board to improve national governance and delivery oversight across the complex system. Substantial funding will be required to design and deliver a transfusion transformation programme.
Scottish Government
In relation to 7b), the Scottish National Blood Transfusion Service (SNBTS) will update its five-year transfusion team plan by 2027 in line with recommendation 7b).
Welsh Government
In relation to 7b), Wales has a Blood Health Plan (BHP) which is regularly reviewed and updated. The Blood Health Plan is overseen by the Blood Health National Oversight Group (BHNOG). While separate from “Transfusion 2024” which applies to England, the BHNOG considers this and other initiatives in the UK when considering plans in Wales. The current BHP acknowledges the need to support the IBI recommendations and the BHNOG has performed a full workplan review, and produced recommendations to support implementation of the IBI recommendations within its remit (primarily recommendation 7). The recommendations have been accepted by the Welsh Government and the All Wales Medical Directors Group. The BHNOG has reviewed its ToR to improve clinical governance and ensure engagement with relevant clinical stakeholders to raise the profile of transfusion safety issues at a health board level and support local implementation.
Northern Ireland Executive
Transfusion 2024 is an NHS England document and was not adopted in Northern Ireland. The most recent transfusion strategy remains the 2011 Better Blood Transfusion 3 Northern Ireland (BBT 3 (NI)), but work is ongoing to update this strategy and produce a new NI Transfusion Strategy under the collaborative leadership of the NI Transfusion Committee (NITC) and NI Blood and Transfusion Service (NIBTS).
This strategy will provide a framework for optimising transfusion practice in Northern Ireland, and will cover all aspects of blood transfusion from donation, through laboratories, to clinical teams, and ultimately, patient safety. The overarching objectives are to ensure the safety, efficiency, and sustainability of blood and blood products, emphasising Patient Blood Management to reduce blood component use and ensuring safe and secure supply and education for clinicians. It will align with national and international best practices, and provide recommendations to benefit patients and the broader healthcare system.
UK Government · 14 May 2025 Written response →
Evidence trail — what's actually happened since
- 15 Jan 2026 · IBCA Community Update As of 13 January 2026: 3,721 people asked to start claims, 3,546 begun process, 3,074 received offers totalling £2.47bn, 2,861 paid totalling £1.89bn. Third compensation regulations in force 31 December 2025. View source → Good Progress
Each entry above links to a primary source — gov.uk written statement, consultation response document, or inspection report. The Index does not characterise government intent; it tracks what has been published.
How this page is built
Source and Response are verbatim from primary documents. The Evidence trail records published activity since — written statements, consultation outcomes, inspection findings, parliamentary references. The Index does not paraphrase or characterise intent; it tracks what has been published. Where the evidence is the absence of action (a missed deadline, a slipped timetable), that absence is documented from primary sources rather than inferred.
This recommendation's data is verified periodically against primary sources. The Index is monitored for staleness weekly.